Videos

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about disparities seen in VHL and its patient population.

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about VHL as a rare disease and resources available for patients to learn more.

The significance of shared decision-making between patients and lung oncologists when considering a novel-based therapy as treatment for non-small cell lung cancer.

Dr. Julie Fisher details the therapies used for HER2-positive breast cancer in the post-operative setting, including newly available treatment options, and reviews data supporting the choice of therapy for each patient.

Considerations for treating patients with non-small cell lung cancer with single-agent immunotherapy vs chemoimmunotherapy.

Dr. Julie Fisher, an expert oncologist, describes the range of treatment options for HER2-positive breast cancer in the pre-operative setting.

View the full CURE® Educated Patient® Webinar: Understanding Myeloproliferative Neoplasms (MPNs) and Treatment Options on demand.

Watch the entire Lung Cancer Heroes® presentation here!

Stephen Liu, MD, and Danielle Hicks clarify the importance of involving patients and caregivers in discussions about non-small cell lung cancer molecular testing.

Thought leaders give an overview on KRAS-mutated non-small cell lung cancer and the treatment options available.

Lisa Laudico provides insight into the value of support groups in metastatic breast cancer.

Julie Larson, LCSW, discusses the concept of self-inventory and questions patients may ask themselves to evaluate their health.

Debbie's Dream Foundation wants every state to recognize November as Curing Stomach Cancer Month, so we've made it easy for you to help make this happen.

View the full CURE Educated Patient Kidney Cancer Summit on demand.

Preferences for repeat biopsies upon progression in non-small cell lung cancer following frontline therapy with a targeted treatment approach.

Jocelyn Mueller, a patient with HER2-positive breast cancer, explains how she received her diagnosis.

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer.

Julie Fisher, MD, gives a brief overview of HER2-positive breast cancer and the tests available for diagnosis.

Stephen Liu, MD, and Danielle Hicks illustrate how molecular testing impacts targeted therapy selection in non-small cell lung cancer.

Key opinion leaders explain how to discuss biomarker testing with non-small cell lung cancer patients, as well as the common questions they field.

People living with metastatic breast cancer share highlights of their personal self-care strategies.

Julie Larson, LCSW, and a panel of women living with metastatic breast discuss the impact of the disease on mental health and resources to consider as a patient.

Knowing the type, phase and eligibility criteria is key in reading cancer research.

The rationale for waiting on results of molecular testing prior to initiating treatment for patients with non-small cell lung cancer.

The difference between tissue and liquid biopsies used in non-small cell lung cancer, and what patients should know about their results and treatment decision-making.

Stephen Liu, MD, and Danielle Hicks describe the purpose and the importance of biomarker testing in non-small cell lung cancer.

Shared insight on novel treatments for non-small cell lung cancer and how patients should advocate for themselves and seek best available care.

Allison Collins shares her experience undergoing a break from therapy after she responded well to treatment for non-small cell lung cancer.

The panel discusses the social impact of metastatic breast cancer diagnosis on the relationships in their lives.

Shirley Mertz, MA, JD, Lisa Laudico, and Sheila McGlown share their stories of being diagnosed with metastatic breast cancer.